Oncothyreon, Inc. (ONTY) is a biotechnology company headquartered in Seattle, WA that is working on treatments for cancer. Its objectives are compassionate; however, a detached viewpoint is necessary to consider its worth for investors. It is not financially self-sustaining, and even though the stock is only priced at $1.77, it is particularly risky. The company's valuation is tied to its development of medical treatments, and though years of testing are required, the odds are against an individual product's approval for commercial use. However, it has several candidates, which increases the probability of one getting through. Further, for those who are willing to write options, costs of being a shareholder may be substantially lowered.
Oncothyreon's web site includes...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: